The mechanisms of Epstein-Barr virus (EBV)-associated tumor development are incompletely understood. The aim of this study was to investigate the gene expression of EBV-associated lymphomas in hu-PBL/SCID mice.
Methods
Human peripheral blood lymphocytes (hu-PBL) from EBV-seropositive donors were transplanted into severe combined immunodeficiency (SCID) mice. In situ hybridization was used to detect EBV-encoded small RNA-1 (EBER1) in tumor tissues. Mutation of TP53 exons 5–8 in EBV-induced lymphomas was analyzed by PCR-SSCP. Immunohistochemical staining was used to examine EBV gene products and cellular oncoproteins.
Results
Twenty-one of 29 mice developed tumors. EBER1 was positive in the nuclei of almost all tumor cells. Immunohistochemistry showed positive staining of LMP1, EBNA2 and ZEBRA in a small number of tumor cells. Immunohistochemically detectable p53 protein expression was common (85.7%), but TP53 gene mutations were identified in only four cases (19.1%) of EBV-associated lymphomas. Positivity rates of C-myc, Bcl-2 and Bax expression were 100%, 95.2%, and 90.5%, respectively, in the 21 cases of EBV-associated lymphomas.
Conclusions
Our preliminary findings suggest that EBV-associated lymphomas in hu-PBL/SCID chimeras show EBV infection, expression of oncogenic viral genes, and overexpression of cellular oncogenes. TP53 gene mutations are rare but p53 protein is commonly expressed in EBV-associated lymphomas.
BoccardoE., VillaL.L.: Viral origins of human cancer. Curr Med Chem, 14: 2526–2539, 2007.
2.
BalfourH.H.Jr., HolmanC.J., HokansonK.M., LelonekM.M., GiesbrechtJ.E., WhiteD.R., SchmelingD.O., WebbC.H., CavertW., WangD.H., BrundageR.C.: A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis, 192: 1505–1512, 2005.
3.
LiH.M., ManC., JinY., DengW., YipY.L., FengH.C., CheungY.C., LoK.W., MeltzerP.S., WuZ.G., KwongY.L., YuenA.P., TsaoS.W.: Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer, 119: 1567–1576, 2006.
4.
De SanjoséS., BoschR., SchoutenT., VerkuijlenS., NietersA., ForetovaL., MaynadiéM., CoccoP.L., StainesA., BeckerN., BrennanP., BenaventeY., BoffettaP., MeijerC.J., MiddeldorpJ.M.: Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. Int J Cancer, 121: 1806–1812, 2007.
FreyN.V., TsaiD.E.: The management of posttransplant lymphoproliferative disorder. Med Oncol, 24: 125–136, 2007.
7.
CarboneA., GloghiniA.: AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol, 130: 662–670, 2005.
8.
MeijerE., CornelissenJ.J.: Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol, 15: 576–585, 2008.
9.
Sebelin-WulfK., NguyenT.D., OertelS., Papp-VaryM., TrappeR.U., SchulzkiA., PezzuttoA., RiessH., SubkleweM.: Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol, 17: 203–210, 2007.
10.
AnnelsN.E., KalpoeJ.S., BrediusR.G., ClaasE.C., KroesA.C., HislopA.D., van BaarleD., EgelerR.M., van TolM.J., LankesterA.C.: Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis, 42: 1743–1748, 2006.
11.
GanR., YinZ., LiuT., WangL., TangY., SongY.: Cyclosporine A effectively inhibits graft-versus-host disease during development of Epstein-Barr virus-infected human B cell lymphoma in SCID mouse. Cancer Sci, 94: 796–801, 2003.
12.
Islas-OhlmayerM., Padgett-ThomasA., Domiati-SaadR., MelkusM.W., CravensP.D., Martin MdelP., NettoG., GarciaJ.V.: Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol, 78: 13891–13900, 2004.
13.
LimW.H., KiretaS., RussG.R., CoatesP.T.: Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood, 109: 1043–1050, 2007.
14.
YajimaM., KandaT., TakadaK.: Critical role of Epstein-Barr virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. J Virol, 79: 4298–4307, 2005.
15.
ClemensM.J.: Epstein-Barr virus: inhibition of apoptosis as a mechanism of cell transformation. Int J Biochem Cell Biol, 38: 164–169, 2006.
16.
NanboA., TakadaK.: The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. Rev Med Virol, 12: 321–326, 2002.
17.
NanboA., YoshiyamaH., TakadaK.: Epstein-Barr virus-encoded poly (A)-RNA confers resistance to apoptosis mediated through Fas by blocking the PKR pathway in human epithelial intestine 407 cells. J Virol, 79: 12280–12285, 2005.
18.
PetosaC., MorandP., BaudinF., MoulinM., ArteroJ.B., MullerC.W.: Structural basis of lytic cycle activation by the Epstein-Barr virus ZEBRA protein. Mol Cell, 21: 565–572, 2006.
HongG.K., KumarP., WangL., DamaniaB., GulleyM.L., DelecluseH.J., PolveriniP.J., KenneyS.C.: Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol, 79: 13984–13992, 2005.
21.
KobayashiH., NagatoT., TakaharaM., SatoK., KimuraS., AokiN., AzumiM., TatenoM., HarabuchiY., CelisE.: Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res, 68: 901–908, 2008.
22.
ThornburgN.J., KulwichitW., EdwardsR.H., ShairK.H., BendtK.M., Raab-TraubN.: LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Oncogene, 25: 288–297, 2006.
23.
ShaminieJ., PehS.C., TanJ.: P53 alterations in sequential biopsies of Asian follicular lymphoma: a study of immunohistochemical staining pattern and gene mutations by PCR-SSCP in paraffin-embedded tissues. Pathology, 37: 39–44, 2005.
24.
RassidakisG.Z., ThomaidesA., WangS., JiangY., FourtounaA., LaiR., MedeirosL.J.: P53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia, 19: 1663–1669, 2005.
25.
SunY., YiH., ZhangP.F., LiM.Y., LiC., LiF., PengF., FengX.P., YangY.X., YangF., XiaoZ.Q., ChenZ.C.: Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett, 581: 131–139, 2007.
